Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of osteoporosis among cancer patients in Germany

Prospective data from an oncological rehabilitation clinic

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

In this prospective study, we measured bone mineral density (BMD) in 1,041 cancer patients undergoing an oncological rehabilitation program in an inpatient rehabilitation clinic. There was an osteoporosis prevalence of approximately 16%, independent of sex, which is considerably higher than in the community-dwelling population.

Introduction

There is evidence that cancer patients are at risk of an increased BMD-loss following the disease and its therapy. Nevertheless, there is only little data available about the prevalence of osteoporosis in German cancer patients. Therefore, we measured BMD in 1,041 oncological inpatients undergoing rehabilitation.

Methods

From February 2006 to September 2009, BMD was measured in oncological patients with dual-energy x-ray absorptiometry (DXA; femur and spine). Statistical analysis for prevalence of osteoporosis was done in descriptive manner calculating means, standard deviation, frequencies, and 95% confidence intervals. To compare the prevalence of osteoporosis in different subgroups, χ 2 tests were done with p < 0.05. To create a risk profile, odds ratios were calculated using uni- and multivariate logistic regression.

Results

In 1,041 patients with a mean age of 57.1 years (11.0 years), DXA-measures were performed. Of them, 22% were male and 78% were female. The osteoporosis prevalence was about 16% (13.8, 18.2), independent of sex (p = 0.9722) or cancer type (p = 0.7174). As risk factors influencing the development of osteoporosis, age, weight, menopausal state, and hormone replacement therapy were identified in women and weight only in men.

Conclusions

Compared to the general population, the rate of osteoporosis is distinctly elevated in German cancer patients independent of sex or cancer type. Hence, a general recommendation for a DXA screening in these patients appears to be justified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Husmann G, Kaatsch P, Katalinic A et al (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7. Ausgabe. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (eds.). Berlin

  2. Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R (2009) Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3:75–88

    Article  PubMed  Google Scholar 

  3. Brown SA, Guise TA (2009) Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr 19:47–60

    PubMed  Google Scholar 

  4. Brown SA, Guise TA (2007) Cancer-associated bone disease. Curr Osteoporos Rep 5:120–127

    Article  PubMed  Google Scholar 

  5. Ito K, Elkin EB, Girotra M, Morris MJ (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152:621–629

    PubMed  Google Scholar 

  6. Michaud LB (2010) Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 67:S20–S30

    Article  CAS  PubMed  Google Scholar 

  7. Ganz PA (2009) Survivorship: adult cancer survivors. Prim Care 36:721–741

    Article  PubMed  Google Scholar 

  8. Morote J, Morin JP, Orsola A et al (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500–504

    Article  PubMed  Google Scholar 

  9. Spanik S, Spanikova B (2010) Bone mineral density in early breast cancer patients. Bratist Lek Listy 111:27–32

    CAS  Google Scholar 

  10. Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA (2009) Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol 27:3605–3610

    Article  PubMed  Google Scholar 

  11. Kaptoge S, da Silva JA, Brixen K et al (2008) Geographical variation in DXA bone mineral density in young European men and women. Results from the Network in Europe on Male Osteoporosis (NEMO) study. Bone 43:332–339

    Article  PubMed  Google Scholar 

  12. Tracy JK, Meyer WA, Flores RH, Wilson PD, Hochberg MC (2005) Racial differences in rate of decline in bone mass in older men: the Baltimore men's osteoporosis study. J Bone Miner Res 20:1228–1234

    Article  PubMed  Google Scholar 

  13. Häussler B, Gothe H, Göl D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study. Osteoporos Int 18:77–84

    Article  PubMed  Google Scholar 

  14. Michaud LB, Goodin S (2006) Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 63:419–430

    Article  PubMed  Google Scholar 

  15. Dachverband Osteologie e.V. (2009) DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Osteologie 18:304–328

    Google Scholar 

  16. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 19:399–428

    Article  CAS  Google Scholar 

  17. Zhang R, Naughton DP (2010) Vitamin D in health and disease. Nutr J 9:65, Epub ahead of print

    Article  CAS  PubMed  Google Scholar 

  18. Neuhouser ML, Sorensen B, Hollis BW et al (2008) Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 88:133–139

    CAS  PubMed  Google Scholar 

  19. Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL (2009) High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27:2151–2156

    Article  CAS  PubMed  Google Scholar 

  20. Vashi PG, Trukova K, Lammersfeld A, Braun DP, Gupta D (2010) Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutr J 9:60

    Article  PubMed  Google Scholar 

  21. Kaptoge S, Reid DM, Scheidt-Nave C et al (2007) Geographic and other determinants of BMD change in European men and women at the hip and spine. A population-based study from the Network in Europe for Male Osteoprosis (NEMO). Bone 40:662–673

    Article  CAS  PubMed  Google Scholar 

  22. Maghraoui AE, Ghazi M, Gassim S et al (2010) Risk factors of osteoporosis in healthy Moroccan men. BMC Musculoskelet Disord 11:148

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Klinik Am Kurpark, Rehazentren DRV-Baden-Württemberg, Kurhausstr. 9, 97688, Bad Kissingen, Germany

    M. Reuss-Borst, U. Hartmann, C. Scheede & J. Weiß

Authors
  1. M. Reuss-Borst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Scheede
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Weiß
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Reuss-Borst.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reuss-Borst, M., Hartmann, U., Scheede, C. et al. Prevalence of osteoporosis among cancer patients in Germany. Osteoporos Int 23, 1437–1444 (2012). https://doi.org/10.1007/s00198-011-1724-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-011-1724-9

Keywords

Search

Navigation